With full membership, watch our educational and editorial videos, search the site, receive our newsletters, join discussions, download slides and much more.
Join Drs Valentin Fuster, Roger Blumenthal, Bob Harrington, Judith Hochman, Sanjay Kaul, Suzanne Oparil, Gregg Stone, Lynne Warner Stevenson, and Bruce Wilkoff as they discuss the results of ARBITER 6-HALTS, the PLATO STEMI subanalysis, the two CHAMPIONs, and CASCADE and tackle the issue of too little, too soon in clinical trials today.
New agents and interventions are paving the way for revised modalities in the management of patients with atrial fibrillation. Join Drs Alpert and Delascio Lopes for a review of the latest findings and options.
How do regulatory pathways differ in the US and UK? Drs Harrington, Bhatt, and Cleland share their experiences and offer insight on how to support innovative research.
Dr Melissa Walton-Shirley talks to Dr Nassir Marrouche about the results of RE-LY, the impact of dronedarone on the treatment of atrial fibrillation, and his hopes for the future of MRI-guided ablation.
Join 'heartwire's Steve Stiles as he talks to Drs Nassir Marrouche and Clyde Yancy about MADIT-CRT, the potential benefits and costs for the heart-failure population in light of the trial, and about why the Europeans seem to be ahead of the guidelines in the European CRT Survey.
Dr Robert Califf sits down with Drs Alfred Bove, Jack Lewin, and Clyde Yancy and AHA CEO Nancy Brown to talk about the ACC and the AHA and their role in the debate on healthcare reform.
Dr Valentin Fuster returns to the city where he was born for a scintillating discussion with Drs Fox, Gershlick, Marrouche, Messerli, Spaulding, Vergheugt, Virmani, and Yancy about the miracle of RE-LY and the striking success of ticagrelor in the PLATO study.
Is it possible and desirable to envisage a nationwide system to screen athletes for hypertrophic cardiomyopathy? Drs Ommen, Maron, and Thompson examine the Italian screening data and review the implications of this model for the US.
Join Drs Valentin Fuster, Anne Curtis, Timothy Gardner, Barry Greenberg, Cindy Grines, Bob Harrington, Sanjay Kaul, Harlan Krumholz, and Salim Yusuf as they unravel the STICH trial and debate the lessons learned from PROTECT-AF in Part 1 of the Cardiology Show. In Part 2 of the program, the JUPITER trial is back on the table and our experts give their opinion on the polypill following the results of the TIPS study.
As theheart.org enters its 10th year join editor-in-chief, Dr Eric Topol, and his guests for a second look at the top news from the past decade. Throughout the coming months, we'll revisit the most important story from each of the last 10 years and ask: How has practice been affected? With time and perspective, what has changed and what have we learned?
Join Dr Melissa Walton-Shirley as she talks to Drs Ileana Piña, Clyde Yancy, and cardiology fellow Eiran Gorodeski about the current state of treatment for decompensated congestive heart failure, why we need to remember the fundamentals, and some exciting data from the PROTECT-1 pilot study.
Join Dr Melissa Walton-Shirley as she talks to Drs Clyde Yancy and Roger Blumenthal about CORONA, RETHINQ, MASTER-1, and the AF/CHF trial and why sticking with the basics might be the best approach for congestive heart failure.
Dr. Ileana Piña discusses the design and outcomes of the MADIT-CRT trial with Drs. Moss and Estes, and how these new data may benefit patients with heart failure.
Does early intervention with CRT-D slow the progression of heart failure? Watch as Dr. David Cannom interviews Drs. Camm, Hlatky, Klein, Moss and Page, and gets their expert opinions on late-breaking clinical trial data released at ESC 09 and how it will affect patient care.
Rate control, rhythm control, new drugs and devices for anticoagulation -- the armamentarium of treatment options is expanding rapidly. Drs. Yancy, Cannon, and Boehmer discuss the latest treatment modalities for patients with AF.
There is an increasing epidemic; the threat is real. With prevalence up and recent therapeutic advances few, atrial fibrillation and the accompanying risk for stroke need to be uppermost in the minds of physicians caring for patients with cardiovascular risk factors. Join Dr. Jerry Naccarelli as he leads a panel of experts consisting of Drs. Osseroff, Capucci and Lau, in a discussion of this global problem.
Read Dr. Jonathan Piccini's review of prevention of stroke in AF and how the newly released results of clinical trials of novel antithrombotic agents will reduce the risk for stroke. Then listen to our international panel of experts, Drs. Camm, Granger, Prystowsky, and Yusuf, as they give their take on new data released at ESC 2009.
Evidence-based therapies, both pharmacologic and devices are well documented in published guidelines, but are they followed and implemented in practice? Is there a treatment gap? Is it all about education or the lack thereof? Drs. Yancy, Abraham, and Pfeffer confer on evidence from recent registries and trials.
The results of MADIT-CRT suggest patients with early stage (NYHA class I/II) symptomatic heart failure (HF) indicated for an implantable cardioverter defibrillator (ICD) may benefit from the addition of cardiac resynchronization therapy (CRT). How likely are these results to increase device implant rates? Take our poll and see how your colleagues responded.
Atrial fibrillation is associated with a high risk for stroke, myocardial infarction, heart failure, and death. How does blockade of the renin-angiotensin system affect patient outcomes? Join our international panel of experts, Drs Camm, Connolly, Crijns, and Granger, as they discuss the ESC 09 hotline results of the ACTIVE-I trial.
Dr. Jeroen Bax, on the cusp of publishing a landmark paper to validate the role of MIBG imaging in risk stratifying patients with heart failure, provides a snapshot of his study in this interview from Europace 2009.